Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;25(6):375-387.
doi: 10.2174/0113894501182288240319074330.

Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets

Roshni Quraishi  1 , Somali Sanyal  1 , Medha Dwivedi  1 , Monika Moitra  1 , Manish Dwivedi  1   2
Affiliations
Review

Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets

Roshni Quraishi et al. Curr Drug Targets. 2024.

Abstract

Gallbladder cancer (GBC) is an uncommon condition in which malignant (cancer) cells are detected in gallbladder tissue. Cancer is often triggered when normal cells turn malignant and begin to spread. Cancer can also be caused by genetic anomalies that result in uncontrolled cell proliferation and tumor development. MicroRNAs (also known as miRNAs or miRs) are a group of small, endogenous, non-coding RNAs of 19-23 nucleotides in length, which play a key role in post-transcriptional gene regulation. These miRNAs serve as negative gene regulators by supervising target genes and regulating biological processes, including cell proliferation, migration, invasion, and apoptosis. Cancer development and progression relate to aberrant miRNA expression. This review demonstrated the implication of various genetic factors and microRNAs in developing and regulating GBC. This suggests the potential of genes and RNAs as the diagnostic, prognostic, and therapeutic targets in gallbladder cancer.

Keywords: Gallbladder cancer; RNAs; epidemiology; genetic factors.; microRNA; risk factors.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Hundal R.; Shaffer E.A.; Gallbladder cancer: Epidemiology and outcome. Clin Epidemiol 2014,6,99-109 - PubMed
    1. Ueno H.; Okusaka T.; Ikeda M.; Takezako Y.; Morizane C.; Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004,91(10),1769-1774 - DOI - PubMed
    1. Acquaviva G.; de Biase D.; Diquigiovanni C.; Argento C.M.; De Leo A.; Bonora E.; Rhoden K.J.; Pession A.; Tallini G.; BRAF exon 15 mutations in papillary carcinoma and adjacent thyroid parenchyma: A search for the early molecular events associated with tumor development. Cancers 2020,12(2),430 - DOI - PubMed
    1. Saito H.; Takada T.; Miyazaki M.; Miyakawa S.; Tsukada K.; Nagino M.; Kondo S.; Furuse J.; Tsuyuguchi T.; Kimura F.; Yoshitomi H.; Nozawa S.; Yoshida M.; Wada K.; Amano H.; Miura F.; Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008,15(1),63-68 - DOI - PubMed
    1. Yin Z.; Yang G.; Qian B.; Liang T.; Guo L.; The multiple molecular signatures in gallbladder carcinoma: From basic studies to clinical application. J Bioinform Syst Biol 2019,2(2) - DOI